Here’s a roundup of recent clinical trial news:
- Exact reports positive results for colorectal cancer screening
Exact Sciences (NSDQ:EXAS) presented data showing that its non-invasive CologuardTM stool-based (sDNA) screening test detected 64 percent of colorectal pre-cancers and 85 percent of cancers. The study was conducted in collaboration with Mayo Clinic and examined more than 1,100 patient samples. Results were presented at the 2010 Special Conference for Colorectal Cancer: Biology to Therapy held by the American Association for Cancer Research in Philadelphia, Pa.
- TYRX completes enrollment in citadel & centurion clinical studies for antibacterial envelope during ICD/CRT replacements
TYRX Inc. announced that it has completed the site enrollment phase of its 50-site CITADEL & CENTURION studies to evaluate the company’s AIGISRx Antibacterial Envelope for use during ICD implantations.
- Coherex Medical launches CE Mark study for its Coherex WaveCrest LAA occluder system in New Zealand
Coherex’s WaveCrest LAA Occluder System was successfully used for the first time in a human; the procedure was performed at Auckland City Hospital in New Zealand by one of the world’s leading cardiologists, Dr. Peter Ruygrok. The new medical device was designed to safely and easily close the Left Atrial Appendage (LAA), a small pouch-like structure found in every human heart and known as a potential breeding ground for blood clots believed to cause 15 percent of all strokes.
- Apollo Endosurgery completes first-in-human cases with new OverStitch endoscopic suturing system
Apollo Endosurgery Inc. announced that their newly-launched OverStitch Endoscopic Suturing System has recently been employed in several, first-in-human cases. OverStitch endoscopic suturing system is a unique device that mimics the way physicians deploy sutures by hand. It provides full-thickness endoscopic suturing on a flexible platform, delivering surgical standard of care through the flexible endoscope.